By: Zoey Becker
Johnson & Johnson and Bayer’s wide spanning VOVAGER PAD study continues to be a gold mine for proving its Xarelto’s worth in several subsets of patients with peripheral artery disease (PAD).
Zoey Becker is a staff writer for Fierce Pharma, specializing in covering the pharmaceutical industry. With a focus on industry news, drug approvals, company acquisitions, and market trends, Zoey provides insightful and up-to-date coverage of the pharmaceutical landscape.
This information evolves through machine learning and human feedback. Improve this profile .